3SBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.08 HKD | +0.50% |
|
+9.35% | -19.15% |
| Apr. 22 | 3Sbio Inc. Announces Management Changes | CI |
| Apr. 15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 22,384 | 22,926 | 15,136 | 13,359 | 17,878 | 13,407 | 13,407 | - |
| Enterprise Value (EV) 1 | 23,886 | 23,645 | 14,959 | 13,120 | 20,196 | 18,543 | 14,272 | 12,425 |
| P/E ratio | 18 x | 23.8 x | 18 x | 8.54 x | 9.91 x | 11 x | 7.4 x | 6.73 x |
| Yield | - | - | - | 3.78% | 1.24% | 2.86% | 3.87% | 4.51% |
| Capitalization / Revenue | 4.88 x | 4.31 x | 2.71 x | 2.09 x | 2.61 x | 2.1 x | 1.55 x | 1.42 x |
| EV / Revenue | 5.21 x | 4.45 x | 2.68 x | 2.06 x | 2.94 x | 2.37 x | 1.65 x | 1.32 x |
| EV / EBITDA | 13.4 x | 11.8 x | 9.31 x | 5.99 x | 7.22 x | 6.7 x | 5.02 x | 4.03 x |
| EV / FCF | 26.5 x | 16.9 x | 33.1 x | 23.9 x | 15.9 x | 10.4 x | 10.4 x | 6.53 x |
| FCF Yield | 3.78% | 5.93% | 3.02% | 4.19% | 6.29% | 9.65% | 9.64% | 15.3% |
| Price to Book | 2.6 x | 2.38 x | 1.41 x | 1.1 x | 1.36 x | 0.93 x | 0.88 x | 0.79 x |
| Nbr of stocks (in thousands) | 2,538,985 | 2,539,974 | 2,543,601 | 2,522,355 | 2,438,845 | 2,382,112 | 2,382,112 | - |
| Reference price 2 | 8.816 | 9.026 | 5.950 | 5.296 | 7.330 | 5.628 | 5.628 | 5.628 |
| Announcement Date | 3/20/19 | 3/30/20 | 3/30/21 | 3/28/22 | 3/21/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,584 | 5,318 | 5,588 | 6,382 | 6,859 | 7,816 | 8,649 | 9,445 |
| EBITDA 1 | 1,782 | 2,005 | 1,606 | 2,190 | 2,796 | 2,768 | 2,841 | 3,083 |
| EBIT 1 | 1,212 | 1,652 | 1,503 | 1,642 | 1,658 | 1,915 | 2,499 | 2,719 |
| Operating Margin | 26.45% | 31.06% | 26.89% | 25.73% | 24.18% | 24.51% | 28.9% | 28.78% |
| Earnings before Tax (EBT) 1 | 1,496 | 1,223 | 979.1 | 1,869 | 2,274 | 1,978 | 2,373 | 2,608 |
| Net income 1 | 1,277 | 973.7 | 835.8 | 1,651 | 1,915 | 1,549 | 1,934 | 2,133 |
| Net margin | 27.86% | 18.31% | 14.96% | 25.87% | 27.92% | 19.82% | 22.36% | 22.59% |
| EPS 2 | 0.4900 | 0.3800 | 0.3300 | 0.6200 | 0.7400 | 0.6200 | 0.7604 | 0.8362 |
| Free Cash Flow 1 | 902.9 | 1,403 | 451.6 | 549.2 | 1,271 | 1,372 | 1,376 | 1,901 |
| FCF margin | 19.7% | 26.38% | 8.08% | 8.61% | 18.53% | 17.61% | 15.91% | 20.13% |
| FCF Conversion (EBITDA) | 50.68% | 69.96% | 28.12% | 25.08% | 45.44% | 50.46% | 48.42% | 61.67% |
| FCF Conversion (Net income) | 70.7% | 144.06% | 54.03% | 33.26% | 66.36% | 67.22% | 71.13% | 89.13% |
| Dividend per Share 2 | - | - | - | 0.2000 | 0.0912 | 0.1608 | 0.2180 | 0.2540 |
| Announcement Date | 3/20/19 | 3/30/20 | 3/30/21 | 3/28/22 | 3/21/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,643 | 2,675 | 2,695 | 2,892 | 3,110 | 3,275 | 3,091 | 3,768 | 3,784 | 4,032 | 4,301 | 4,576 | 4,445 | 5,193 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | 915.3 | 727 | 802.5 | 855.8 | 1,301 | 614.8 | 1,411 | 1,296 | 1,478 | 1,476 |
| Operating Margin | - | - | - | - | 29.43% | 22.2% | 25.96% | 22.71% | 34.38% | 15.25% | 32.79% | 28.32% | 33.25% | 28.42% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | 0.1300 | 0.2500 | 0.2700 | 0.0600 | 0.3400 | 0.2800 | 0.3700 | 0.3700 | 0.3900 | 0.2300 | 0.4300 | 0.3900 | 0.4500 | 0.4400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/21/19 | 3/30/20 | 8/17/20 | 3/30/21 | 8/25/21 | 3/28/22 | 8/24/22 | 3/21/23 | 8/24/23 | 3/20/24 | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 1,502 | 719 | - | - | 2,318 | 2,148 | 866 | - |
| Net Cash position 1 | - | - | 177 | 239 | - | - | - | 982 |
| Leverage (Debt/EBITDA) | 0.843 x | 0.3587 x | - | - | 0.8291 x | 0.776 x | 0.3047 x | - |
| Free Cash Flow 1 | 903 | 1,403 | 452 | 549 | 1,271 | 1,372 | 1,376 | 1,901 |
| ROE (net income / shareholders' equity) | 16% | 10.7% | 8.23% | 15.1% | 15.2% | 11.5% | 12.5% | 12.4% |
| ROA (Net income/ Total Assets) | 9.26% | 6.8% | 5.15% | 8.95% | 9.3% | 6.79% | 8.23% | 8.38% |
| Assets 1 | 13,796 | 14,324 | 16,244 | 18,445 | 20,601 | 22,817 | 23,492 | 25,469 |
| Book Value Per Share 2 | 3.390 | 3.800 | 4.220 | 4.810 | 5.400 | 6.040 | 6.400 | 7.110 |
| Cash Flow per Share 2 | 0.4200 | 0.7400 | 0.4900 | 0.5700 | 0.8200 | 0.8400 | 0.7700 | 1.170 |
| Capex 1 | 247 | 471 | 893 | 1,029 | 910 | 820 | 905 | 842 |
| Capex / Sales | 5.4% | 8.86% | 15.98% | 16.13% | 13.26% | 10.52% | 10.47% | 8.91% |
| Announcement Date | 3/20/19 | 3/30/20 | 3/30/21 | 3/28/22 | 3/21/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
5.628
CNY
Average target price
6.887
CNY
Spread / Average Target
+22.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.15% | 1.85B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 1530 Stock
- Financials 3SBio Inc.
